Here are the Form 4 insider transactions from Larimar Therapeutics, Inc. (LRMR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow LRMR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LRMR filings page.
Larimar Therapeutics, Inc. Chief Medical Officer Clayton Russell reported a direct purchase of 3,322 common shares on November 16, 2026, at $3.01 per share. He reported direct holdings of 74,765 shares after the purchase. No Rule 10b5-1 plan is reported, and the transaction is described as a purchase in the open market or a private transaction.
Larimar Therapeutics, Inc. (LRMR) director Jeffrey W. Sherman purchased 3,289 shares of common stock on November 16, 2026, at $3.0576 per share. His directly held position following the purchase was 8,289 shares. The transaction was not made under a Rule 10b5-1 trading plan. It is described as a purchase in the open market or a private transaction.
Larimar Therapeutics, Inc. director Thomas Edward Hamilton reported that Cure FA Foundation, Inc. purchased 70,000 common shares on November 12, 2026, at a weighted average price of $2.6726 per share. No Rule 10b5-1 plan is reported.
Hamilton reported holding 714,798 shares directly and 159,433 shares indirectly through Post Edison, LLC.
Larimar Therapeutics, Inc. (LRMR) President and CEO Carole Ben-Maimon purchased 18,050 shares on November 11, 2026, at a reported weighted-average price of $2.7675 per share; the purchases occurred in multiple transactions priced from $2.765 to $2.77, inclusive. Each share is represented by a restricted stock unit, a contingent right to receive one common share upon settlement. Her reported direct holdings after the purchase were 386,326 shares.
Larimar Therapeutics, Inc. (LRMR) director Frank E. Thomas purchased 8,000 shares of common stock on November 11, 2026, at $2.7250 per share. His directly held position following the purchase was 15,000 shares. No Rule 10b5-1 plan is reported for the purchase.
Larimar Therapeutics, Inc. director Joseph Truitt purchased 3,500 shares of common stock on November 11, 2026, at a weighted average price of $2.7976 per share. He directly held 6,250 shares after the purchase, and no Rule 10b5-1 plan is reported.
Larimar Therapeutics, Inc. President and COO John B. Harlow Jr. purchased 17,800 shares of common stock on November 11, 2026. The reported weighted average price was $2.8044 per share, across multiple transactions ranging from $2.7295 to $2.825 per share. He directly held 67,800 shares after the purchases. No Rule 10b5-1 plan is reported.
Larimar Therapeutics, Inc. Chief Financial Officer Michael Celano purchased 18,460 shares of common stock on November 11, 2026, at a weighted-average price of $2.7081 per share. Celano directly held 234,245 shares following the purchase. No Rule 10b5-1 plan is reported.
Larimar Therapeutics, Inc. Chief Development Officer Gopi Shankar purchased 5,000 common shares on November 11, 2026, at $2.7098 per share. He reported direct ownership of 81,443 shares after the purchase. The purchase may have been in the open market or a private transaction; no Rule 10b5-1 plan is reported.
On September 29, 2026, Larimar Therapeutics, Inc. (LRMR) President and COO John B. Harlow Jr. received 50,000 restricted stock units, each a contingent right to one common share upon settlement, and an option to buy 800,000 common shares at $3.14 per share. The option expires September 29, 2036.
Larimar Therapeutics director Thomas Edward Hamilton bought additional common stock in the company. He purchased 50,000 shares in an open-market transaction at a weighted average price of $3.3378 per share, with individual trades ranging from $3.33 to $3.35. Following the purchase, he holds 714,798 common shares directly and 159,433 shares indirectly through Post Edison, LLC.
Larimar Therapeutics reported that an entity associated with Deerfield Management received a grant of stock options linked to 55,150 shares of common stock. The options have an exercise price of $3.33 per share and expire on May 19, 2036.
The option was granted to Jonathan S. Leff, who serves on Larimar’s board, but is held for the benefit and at the direction of Deerfield Management Company, L.P. It is scheduled to vest on the earlier of May 19, 2027 or the date of Larimar’s next annual stockholder meeting, subject to Leff’s continued board service. The reporting persons disclaim beneficial ownership beyond any indirect pecuniary interest.
Larimar Therapeutics, Inc. disclosed that an entity associated with director Jonathan S. Leff received a grant of stock options covering 55,150 shares of common stock. The options have an exercise price of $3.33 per share, expire on May 19, 2036, and were granted as compensation.
According to the disclosure, Leff, a partner in Deerfield Management Company, L.P., has no pecuniary interest in these options and disclaims beneficial ownership, holding them for the benefit and at the direction of Deerfield Management Company, L.P. The options vest on the earlier of May 19, 2027 or the company’s next annual stockholder meeting, subject to his continued service on the board.
Larimar Therapeutics director Jeffrey W. Sherman received a grant of 55,150 stock options for common stock. These options carry an exercise price of $3.33 per share and expire on May 19, 2036. They vest on the earlier of May 19, 2027 or the company’s next annual stockholder meeting, subject to his continued board service. This is a compensation-related award rather than an open-market trade, and no common shares were bought or sold in this filing.
Larimar Therapeutics, Inc. director Joseph Truitt reported receiving a stock option grant covering 55,150 shares of common stock. The option has an exercise price of $3.33 per share and expires on May 19, 2036.
These options vest on the earlier of May 19, 2027, or the date of Larimar’s next annual meeting of stockholders, in each case contingent on Truitt’s continued service on the Board of Directors. Following this grant, Truitt holds 55,150 stock options directly.
Larimar Therapeutics director Frank E. Thomas received a new stock option grant as equity compensation. He was awarded options to purchase 55,150 shares of common stock at an exercise price of $3.33 per share, with no cash paid at grant.
The options vest on the earlier of May 19, 2027 or the date of Larimar’s next annual stockholder meeting, in each case only if he continues serving on the board. Following this grant, he holds 55,150 stock options directly, highlighting a routine, service-based incentive award rather than an open-market trade.
Larimar Therapeutics director Thomas Edward Hamilton received a grant of stock options covering 55,150 shares of common stock. The options have an exercise price of $3.33 per share and expire on May 19, 2036. They vest on the earlier of May 19, 2027 or the company’s next annual stockholder meeting, subject to his continued service on the board. Following this grant, he holds 55,150 options directly.
Larimar Therapeutics, Inc. reported that investment funds managed by Deerfield entities associated with James E. Flynn made significant open-market purchases of its common stock. On February 27, 2026, Deerfield Private Design Fund III, L.P., Deerfield Private Design Fund IV, L.P., Deerfield Healthcare Innovations Fund, L.P., and Deerfield Partners, L.P. collectively bought 5,000,000 shares of Larimar common stock at $5.00 per share in indirect transactions. Following these purchases, each fund reported updated indirect holdings in Larimar, while the reporting persons collectively disclaimed beneficial ownership beyond any indirect pecuniary interest described in the footnotes.
Larimar Therapeutics, Inc. director Thomas Edward Hamilton bought 100,000 shares of common stock in an underwritten offering at $5.00 per share, which closed on February 27, 2026. Following this open-market purchase, he directly owns 664,798 shares and indirectly holds 159,433 shares through Post Edison, LLC.
Larimar Therapeutics director Frank E. Thomas bought common stock in the company through its underwritten offering. On February 27, 2026, he purchased 5,000 shares of Larimar Therapeutics common stock at $5.00 per share in an open-market style purchase tied to the offering. After this transaction, he directly owned 7,000 shares of common stock.
Larimar Therapeutics director Jeffrey W. Sherman bought 5,000 shares of the company’s common stock at $5.00 per share in an underwritten offering that closed on February 27, 2026. The transaction is reported as a direct, open-market style purchase on a Form 4 insider filing.
Larimar Therapeutics reported an insider equity award for Chief Development Officer Shankar Gopi. On January 26, 2026, he received 153,822 stock options with a $3.60 exercise price and vesting over four years, starting 25% on January 26, 2027, then monthly thereafter.
He also acquired 25,637 shares of common stock for $0.00 per share, represented by restricted stock units, bringing his directly held common stock to 76,443 shares. All transactions were classified as awards and reported as directly owned.
Larimar Therapeutics Chief Medical Officer Clayton Russell received new equity awards. On January 26, 2026, he was granted 25,637 restricted stock units, representing the right to receive an equal number of Larimar common shares at settlement, bringing his directly held common stock to 71,443 shares.
He was also granted stock options for 153,822 shares at an exercise price of $3.60. These options vest 25% on January 26, 2027, with the remaining 75% vesting in equal monthly installments over the following 36 months, contingent on continued service.
Larimar Therapeutics President and CEO Carole Ben-Maimon reported equity awards dated January 26, 2026. She received 100,100 shares of Common Stock for no cash cost, structured as restricted stock units that each convert into one share upon settlement.
She was also granted a stock option for 600,600 shares of Common Stock at an exercise price of $3.60 per share. The option vests 25% on January 26, 2027, with the remaining 75% vesting in equal monthly installments over the following 36 months, subject to her continued service. After these grants, she directly holds 368,276 shares of Common Stock and 600,600 stock options, while several irrevocable family trusts for which she serves as trustee each hold 31,155 or 31,156 shares; she disclaims beneficial ownership of those trust shares except to any pecuniary interest.
Larimar Therapeutics reported an equity compensation grant to its Chief Financial Officer, Michael Celano. On January 26, 2026, he received 37,604 shares of Common Stock at a price of $0.00 per share, represented by restricted stock units that each convert into one share upon settlement. Following this award, he beneficially owned 215,785 shares of Common Stock directly. The same day, he was also granted a stock option covering 225,622 shares of Common Stock with a $3.6 exercise price per share. This option vests 25% on January 26, 2027, with the remaining 75% vesting in equal monthly installments over the next 36 months, contingent on his continued service, and expires on January 26, 2036.